[T2HD Study. Oral anticoagulants and antiplatelet agents: Practices, benefits, and risks in the chronic hemodialysis population. Observational data].
Fiche publication
Date publication
juin 2016
Journal
Nephrologie & therapeutique
Auteurs
Membres identifiés du Cancéropôle Est :
Pr THILLY Nathalie
Tous les auteurs :
Martin A, Thilly N, Ayav C, Clerc-Urmes I, Held P, Frimat L, Peters NO
Lien Pubmed
Résumé
Chronic hemodialysis patients have disorders of hemostasis associated with End Stage Renal Disease, cardiovascular disease, and treatments they receive. They have more thrombotic and bleeding events than the general population. The balance of risks and benefits of drugs is not precisely defined. The aim of this study is to describe the practices patterns concerning oral anticoagulants (AVK) and antiplatelet agents (APA), and to investigate their impact on the survival and the occurrence of thrombotic and bleeding events.
Mots clés
Administration, Oral, Aged, Anticoagulants, adverse effects, Cohort Studies, Female, Hemorrhage, chemically induced, Humans, Male, Platelet Aggregation Inhibitors, adverse effects, Practice Patterns, Physicians', Renal Dialysis, Retrospective Studies, Risk Assessment, Thrombosis, chemically induced
Référence
Nephrol. Ther.. 2016 Jun;12(3):156-65